Vilon (KE)
KE Dipeptide | Thymus Immune Bioregulator
Community Research
Join others researching Vilon — share findings, ask questions, and learn from real experiences
Vilon is a Khavinson bioregulator dipeptide (KE) consisting of lysine and glutamic acid, originally isolated from thymus gland extracts. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it acts as a molecular signaling compound that restores normal gene expression and protein synthesis in immune and epithelial cells. Research shows Vilon increases mean lifespan by 20-40% in animal studies and suppresses tumor development.
Vilon works through epigenetic modulation, restoring chromatin structure and gene expression in immune cells. It stimulates thymocyte proliferation, activates T-helper cells, and increases the proliferative index in thymus tissue (from 26% to 37% in studies). The peptide modulates tyrosine phosphorylation of mitogen-activated cytoplasmic kinases and helps rejuvenate aged immune systems by restoring proper gene expression patterns.
Molecular Data
KELysine
Position 1
Glutamic Acid
Position 2
Research Indications
Stimulates thymocyte proliferation and enlarges thymic lobules.
Activates T-helper cells and improves immune response.
Restores chromatin structure and gene expression in aged lymphocytes.
Long-term treatment increased mean lifespan 20-40% in rodent studies.
Suppresses development of spontaneous and induced tumors.
Promotes recovery in tissues exposed to radiation damage.
Restores brush border membrane enzyme levels in aged animals.
Enhances intestinal barrier function in aged rats.
Dosing Protocols
Available in capsule form for oral administration. As the shortest Khavinson peptide (just 2 amino acids), Vilon is easily absorbed orally. Typical protocol involves 10-20 day cycles, repeated 2-3 times per year.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard protocol | 10-20 mg | Daily for 10-20 days | Oral capsules |
| Maintenance | 10 mg | 2-3 cycles yearly | Oral capsules |
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Generally well-tolerated
- Minimal side effects reported
Stop Signs - Discontinue if:
- Allergic reactions
- Unusual immune symptoms
Contraindications
- Active autoimmune flares (consult physician)
- Known hypersensitivity
- Pregnancy or breastfeeding
Quality Checklist
Good Signs
- White powder or capsules
- Clear solution if reconstituted
- Proper packaging and labeling
Warning Signs
- Unknown source or purity
Bad Signs
- Discoloration
- Unusual odor
- Damaged packaging
Frequently Asked Questions
How significant is the 20-40% lifespan extension from Vilon - is it proven in humans?
Animal studies showed 20-40% mean lifespan increases with long-term Vilon treatment plus tumor suppression. These are compelling preclinical findings but haven't been replicated in human longevity trials - lifespan extension is theorized based on mechanisms and animal models rather than clinical proof. Effects in humans are likely more modest.
Can Vilon be used continuously or must it follow the 10-20 day cycling protocol?
Vilon follows Khavinson bioregulator cycling: 10-20 days on, then off, repeated 2-3 times yearly. Cycling allows the body's natural feedback mechanisms to maintain homeostasis and prevents tolerance. Continuous use isn't recommended and may blunt epigenetic effects through feedback inhibition.
Does Vilon improve intestinal health and can it help with digestive issues?
Yes, Vilon restores brush border membrane enzyme levels and enhances intestinal barrier function in aged animals. This suggests potential benefits for age-related digestive decline and GI barrier integrity. However, direct clinical data for specific digestive conditions is limited - benefits are inferred from mechanisms.
Is Vilon the shortest bioregulator peptide and does size matter for absorption?
Yes, Vilon is the shortest Khavinson peptide at just 2 amino acids, giving it excellent oral absorption. The dipeptide size allows convenient capsule administration with good GI bioavailability - making it more practical than longer peptide bioregulators requiring injection.
References
- Peptide Bioregulators Increase LifespanBiogerontology (2003)
Long-term treatment with peptide preparations including Vilon increased mean lifespan 20-40% and suppressed tumorigenesis.
- Vilon Effects on Aged LymphocytesBulletin of Experimental Biology and Medicine (2002)
Vilon improved lymphocytes from old people by restoring chromatin structure and gene expression.
- Peptides Regulating Proliferative Activity in THP-1 CellsPMC (2022)
Vilon and other Khavinson peptides modulate key proliferative patterns and tyrosine phosphorylation of kinases.
- Short Peptide Immunoprotecting PropertiesAdvances in Gerontology (2018)
Vilon and related peptides possess age-associated immunoprotecting properties in the spleen.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.